A Systematic Review and Meta-regression Analysis of Study Design Variables associated with Attrition in Randomised Controlled Trials of Antidepressants used in the Treatment of Major Depressive Disorder

**Introduction**

Major Depressive Disorder (MDD) is the number one psychological disorder in the western world. By 2020 it is predicted MDD will be the second most disabling condition worldwide behind heart disease. It is estimated that 1 in 5 adults in the United Kingdom (UK) show symptoms of depression. Antidepressants are currently the mainstay treatment for (MDD). In 2015, 61.0 million antidepressant items were prescribed in the U.K, which is 31.6 million (107.6%) more than in 2005.

Within the UK, over two dozen different antidepressants have been approved as safe and effective treatments for MDD. The National Institute for Health and Care Excellence (NICE) clinical guidance on depression in adults; concludes that antidepressants have largely equal efficacy and the choice should depend on the side-effect profile, previous experience of treatments, tendency to cause discontinuation symptoms, interactions and cost. Despite the availability of a multitude of different antidepressants, in practice more than 40% of patients on antidepressants prematurely stop treatment within three months. There is a still a need for new novel antidepressants, with better efficacy, quicker onset of action and higher rates of remission and response in patients with MDD.

The need for new antidepressants is compounded during development, as up to 36% of participants within randomised controlled trials (RCTs) dropout of the trial. Attrition (dropout, withdrawal, loss to follow up, premature discontinuation) of 20% or greater raises concerns about the possibility of attrition bias and serious threats to validity. Whilst RCTs are mandatory to meet regulatory requirements for the approval of new antidepressants, there are no recommendations in the design of trials to reduce attrition. In particular, limited research exists investigating the association of study design variables (such as number of treatment arms, number of treatment assessments, fixed or flexible treatment schedule, control type, ratio of treatment allocation, number of study sites, trial duration, baseline depression severity, clinical setting, country of study location and sponsor type) with attrition. No studies have been undertaken examining study design variables relating to attrition of MHRA (UK) approved antidepressants. This review will aid researchers and clinical trial decision
makers, to predict attrition and subsequently make adjustments to the study design to minimise attrition and related threat to trial validity.

**Aims**

- To investigate study design variables associated with attrition in parallel double-blind, placebo and/or active comparator controlled RCTs of MHRA (UK) approved antidepressants used to treat Major Depressive Disorder.
- To generate a model to predict attrition in parallel double-blind, placebo and/or active comparator controlled RCTs of antidepressants used to treat Major Depressive Disorder.

**Search Methods**

Systematic reviews help to establish whether clinical findings are consistent and can be generalised across populations and settings. Data was gathered from a number of sources: electronic searches (Medline, Embase, Psychinfo, Cochrane and Google Scholar, COPAC); trial registries (including clinicaltrials.gov, EU Clinical Trials Register and WHO International Clinical Trials Registry); lastly pharmaceutical companies and the UK regulatory medication authority MHRA.

**Selection Criteria**

Study criteria included published and non-published parallel double-blind, placebo-controlled and/or active comparator(s) controlled randomised controlled trials of MHRA (UK) approved antidepressants used to treat Major Depressive Disorder. Adults aged over 18 years of age suffering from moderate or severe Major Depressive disorder were included.

**Data Collection**

The review author screened articles for inclusion, extracted data and analysed the results. Data extraction was completed using a modified data extraction form based on Cochrane Collaboration recommendations.
**Main Results**

The included trials had an overall mean attrition of 19.80%. Two predictive regression models were found to be significant. The first included two treatment arms \((p = 0.03)\) and pharmaceutically sponsored studies \((p = 0.023)\) significantly increased attrition, by 5.95% and 8.0% respectively. The second model from a sensitivity analysis found multi-site \((p = <0.001)\), studies conducted in the USA \((p = 0.006)\) and three or more treatment arms \((p = 0.045)\) significantly reduced attrition by 24.36%, 6.66% and 4.5% respectively. Whereas large sample sizes increased attrition by 0.018% per added participant \((p = 0.047)\).

**Conclusion**

The results of this review found the predictive model: multi-site, studies conducted in the USA, three or more treatment arms and large sample sizes as the more accurate predictive model out of the two. Although not tested as a possible predictor, placebo-controlled arms were significantly associated with decreased attrition. Importantly the nature of this review is a relevant topic and has helped to quantify the predicted attrition for studies either at the funding stage, design stage or for studies underway.

Despite the significance of this model it may not be feasible in practice to encompass all variables in the study design to reduce attrition. In particular conducting research in the USA alone or using smaller sample sizes would not be suitable or practical for licensing of new antidepressants. In parallel the research is restricted to defined population, drug and RCT design.